Professor Stricker has been at the forefront in the use of irreversible electroporation (NanoKnife) as a form of focal therapy in the treatment of intermediate-risk prostate cancer. Having performed almost 350 cases since February 2013 and being involved in several trials and international registries, he was invited recently to give his intermediate results for comparison to some of the other technologies available. The results to date both in terms of cancer clearance of the primary tumour, recurrence rates, side effect profile and salvage surgery were well received. His conclusion was that the intermediate results were encouraging with a remarkably low side effect profile. Nanoknife focal therapy a strong contender for being one of the major technologies to potentially treat focal prostate cancer.